Medication info
Duo Telmisartan/Atorvastatin Tablet 80/20 mg

Duo Telmisartan/Atorvastatin Tablet 80/20 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hankook HyuTex Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP×3]
Approval status
Active

MFDS item code 202005518 · Approved 2020.07.29 · Insurance code 649105030

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
In a drug interaction study of the active ingredients in this medicine, telmisartan 80mg and rosuvastatin 20mg, telmisartan Cmax was approximately 0.87-fold and AUC approximately 1.00-fold in the presence of rosuvastatin, while rosuvastatin Cmax increased approximately 1.71-fold and AUC approximately 1.16-fold in the presence of telmisartan. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor the patient closely. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily. A dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular disease risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular disease morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular disease risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Hankook HyuTex Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who require simultaneous treatment with telmisartan and atorvastatin. Telmisartan is primarily used for the treatment of essential hypertension and helps to reduce the risk of myocardial infarction, stroke, and cardiovascular mortality in patients over 55 years old who are at high risk for cardiovascular disease or who cannot use ACE inhibitors. Atorvastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemia when diet and exercise are not sufficient, lowering total cholesterol and LDL cholesterol levels to delay the progression of atherosclerosis. Additionally, it is used as an adjunct to dietary therapy in patients with hypercholesterolemia and abnormal beta-lipoproteinemia. In high-risk populations with cardiovascular risk factors, it helps to reduce the risk of stroke, myocardial infarction, and vascular revascularization. This medication is therefore used to manage both hypertension and hyperlipidemia simultaneously and improve cardiovascular health.

How to take

Adult dose

In a drug interaction study of the active ingredients in this medicine, telmisartan 80mg and rosuvastatin 20mg, telmisartan Cmax was approximately 0.87-fold and AUC approximately 1.00-fold in the presence of rosuvastatin, while rosuvastatin Cmax increased approximately 1.71-fold and AUC approximately 1.16-fold in the presence of telmisartan. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor the patient closely. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily. A dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular disease risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular disease morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular disease risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This medication poses a significant risk of serious harm or death to the fetus and newborn if taken during pregnancy, hence treatment should be stopped immediately upon confirmation of pregnancy. Women who are pregnant or breastfeeding, and women of childbearing age who are not using appropriate contraception should not take this medication. Patients with severe liver impairment, bile duct obstruction, active liver disease, myopathy, hereditary angioedema, or severe renal impairment should also avoid using this medication. Elderly patients, those with hyperkalemia, and those with mild to moderate liver dysfunction should use this medication with caution, with regular monitoring of liver function tests and muscle-related symptoms. If symptoms such as myalgia, muscle weakness, or muscle cramps occur, consult a physician immediately, and check for muscle damage through blood tests. This medication may interact with other specific medications, so always inform healthcare providers of other medications being taken. This medication is primarily metabolized in the liver, and regular testing of liver enzyme levels should be conducted if liver function is impaired. It should not be used during pregnancy or breastfeeding, particularly in women who could become pregnant, who should use appropriate contraceptive methods. Safety and effectiveness in children have not been established; therefore, it is not recommended for pediatric use. In case of overdose, symptoms may include hypotension, dizziness, and acute renal failure, so immediate medical attention is required. This medication may cause drowsiness or dizziness; caution should be exercised when driving or operating hazardous machinery. Keep out of reach of children and do not store in other containers for safety.

Side effects

Headache, positional vertigo, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disorders, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, indigestion, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver function abnormality, liver disorder, increased sweating, pruritus, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased blood creatinine, increased blood uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, arrhythmia, weakness, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, inadequate effect, joint pain, numbness, chest discomfort, anorexia, abdominal bloating, abnormal liver function tests, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, and should therefore be stored in a tightly closed container. The suitable storage temperature is room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.